BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

/PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb)...

Related Keywords

Zhongshan , Anhui , China , Chinese , Biocity Biopharma , Jia Fan , Prnewswire Biocity Biopharma , Astrazeneca , Chinese Academy Of Sciences , City Biopharma , Zhongshan Hospital , Chinese Academy ,